2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Eukaryotic Initiation Factor (eIF)

Eukaryotic Initiation Factor (eIF)

Eukaryotic Initiation Factor (eIF)

Related Products

PDF 0.58 MB

Eukaryotic initiation factors (eIFs) are proteins involved in the initiation phase of eukaryotic translation. These proteins help stabilize the formation of the functional ribosome around the start codon and also provide regulatory mechanisms in translation initiation.

Eukaryotic initiation factor 2B (eIF2B) is a guanine nucleotide-exchange factor which mediates the exchange of GDP (bound to initiation factor eIF2) for GTP, thus regenerating the active [eIF2.GTP] complex that is required for peptide-chain initiation. The activity of eIF2B is a key control point for eukaryotic protein synthesis and is altered in response to viral infection, hormones, nutrients, growth factors and certain stresses.

Eukaryotic translation initiation factor 4E (eIF4E) is best known for its function in the initiation of protein synthesis on capped mRNAs in the cytoplasm. Eukaryotic initiation factor (elF) 4A functions as a subunit of the initiation factor complex elF4F, which mediates the binding of mRNA to the ribosome.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-12495A
    ISRIB
    		Antagonist 99.0%
    ISRIB is a brain-penetrant inhibitor of integrated stress response (ISR). Persistent activation of the ISR has been linked to the development of several neurological disorders as ISR represses translation through inhibiting eIF2B. ISRIB inhibits the ISR by promoting the nucleotide exchange activity of eIF2B and recovering the translation, and thus can be used for neurological disorders research.
    ISRIB
  • HY-112654
    GCN2iB
    		Inhibitor 99.83%
    GCN2iB is an ATP-competitive, selective GCN2 inhibitor with an IC50 of 2.4 nM. GCN2iB inhibits the activation of the GCN2 pathway and upregulates GPX4. GCN2iB enhances the anticancer effect of ASNase against acute lymphoblastic leukemia. GCN2iB increases left ventricular ejection fraction, while reducing fasting blood glucose and myocardial fibrosis. GCN2iB can be used in research related to acute lymphoblastic leukemia, acute myeloid leukemia and diabetic cardiomyopathy.
    GCN2iB
  • HY-108666
    ATPγS tetralithium salt
    		Chemical ≥98.0%
    ATPγS (tetralithium salt) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATPγS (tetralithium salt) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATPγS (tetralithium salt) is active in ATP hydrolysis.
    ATPγS tetralithium salt
  • HY-100877
    GCN2-IN-1
    		Inhibitor 99.46%
    GCN2-IN-1 is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with an IC50 of <0.3 μM in the enzyme assay and an IC50 of 0.3-3 μM in the cell assay.
    GCN2-IN-1
  • HY-19831
    4EGI-1
    		Inhibitor 98.69%
    4EGI-1 is an inhibitor of eIF4E/eIF4G interaction, with a Kd of 25 μM against eIF4E binding.
    4EGI-1
  • HY-W141446
    VT00065
    		Inhibitor
    VT00065 is a covalent DHS inhibitor. VT00065 forms a redox-dependent covalent bond with the catalytic lysine K329 of DHS, locking the enzyme in an inactive state.
    VT00065
  • HY-179524
    ISR activator 2
    		Activator
    ISR activator 2 is a selective ISR activator. ISR activator 2 can preferentially activate the ISR through the binding of the cytosolic pattern recognition receptor RIG-I, which subsequently activates the heme-regulated inhibitor (HRI) ISR kinase independent of an interferon response. ISR activator 2 can be used for the study of pancreatic cancer.
    ISR activator 2
  • HY-181959
    APL-4098
    		Inhibitor
    APL-4098 is an orally active, selective, ATP-competitive GCN2 inhibitor with a Ki of 4.39 nM and a Kd of 2.9 nM. APL-4098 reduces the phosphorylation level of eIF2α and the expression level of ATF4. APL-4098 impairs mitochondrial function and exerts cytotoxic effects on primary acute myeloid leukemia cells. APL-4098 is applicable to research related to acute myeloid leukemia.
    APL-4098
  • HY-112163
    Zotatifin
    		Inhibitor 99.69%
    Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC50=2 nM) and interferes with the assembly of the eIF4F initiation complex. Zotatifin shows robust antiviral effects, it effectively reduces viral infectivity by inhibiting SARS-CoV-2 NP protein biogenesis (IC90=37 nM). Zotatifin induces cell apoptosis.
    Zotatifin
  • HY-19356
    Rocaglamide
    		Inhibitor 99.34%
    Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC50 of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia.
    Rocaglamide
  • HY-125021
    2BAct
    		Activator 99.77%
    2BAct is a highly selective, orally active, and CNS-penetrant eIF2B (eukaryotic initiation factor 2B) activator with an EC50 of 33 nM. 2BAct prevents neurological defects caused by a chronic integrated stress response. 2BAct displays improved solubility and pharmacokinetics relative to eIF2B activator ISRIB trans-isomer (HY-12495).
    2BAct
  • HY-13251
    Silvestrol
    		Inhibitor 99.96%
    Silvestrol is a eukaryotic translation initiation factor 4A (eIF4A) inhibitor isolated from Agave americana Linn.. Silvestrol induces autophagy and caspase-mediated apoptosis.
    Silvestrol
  • HY-145974A
    m7GpppAmpG ammonium solution (100 mM)
    		Ligand 99.96%
    m7GpppAmpG ammonium (m7G(5')ppp(5')(2'OMeA)pG ammonium) is a trinucleotide 5′ end cap analog. m7GpppAmpG ammonium binds to eIF4E with a KD value of 45.6 nM. m7GpppAmpG ammonium caps RNA with a capping efficiency of 90%. m7GpppAmpG ammonium enhances mRNA stability and translation efficiency. m7GpppAmpG ammonium is used in mRNA therapeutic research.
    m7GpppAmpG ammonium solution (100 mM)
  • HY-14307
    Necrocide 1
    		Activator 99.55%
    Necrocide 1, a necrosis by sodium overload (NECSO) inducer, is a selective transient receptor potential melastatin 4 (TRPM4) agonist with an EC50 of 306.3 nM for human TRPM4. Necrocide 1 triggers TRPM4-dependent necrotic cell death through the induction of sodium influx. Necrocide 1 induces hallmarks of immunogenic cell death incurring calreticulin (CALR) exposure, ATP secretion and high mobility group box 1 (HMGB1) release. Necrocide 1 can be used for the study of breast and prostate cancer.
    Necrocide 1
  • HY-W050044
    L-Azetidine-2-carboxylic acid
    		Activator 99.97%
    L-Azetidine-2-carboxylic acid is a proline analog. L-Azetidine-2-carboxylic acid upregulates the lipid autophagy marker LC3-II via activation of the PERK pathway. L-Azetidine-2-carboxylic acid increases pro-apoptotic BAX protein. L-Azetidine-2-carboxylic acid induces ATF6 cleavage and upregulates phosphorylated eIF2α levels. L-Azetidine-2-carboxylic acid induces ER stress, inducing protein misfolding and aggregation. L-Azetidine-2-carboxylic acid shows teratogenic, pro-inflammatory and pro-apoptotic effects.
    L-Azetidine-2-carboxylic acid
  • HY-158201
    ATF4-IN-1
    		Activator 99.29%
    ATF4-IN-1 (Compound 21) is an ATF4 inhibitor and also an eIF2B activator. ATF4-IN-1 can be used in research on neurodegenerative diseases.
    ATF4-IN-1
  • HY-136453
    CR-1-31-B
    		Inhibitor 98.38%
    CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor. CR-1-31-B exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis. CR-1-31-B perturbs association of Plasmodium falciparum eIF4A (PfeIF4A) with RNA. CR-1-31-B induces apoptosis of neuroblastoma and gallbladder cancer cells.
    CR-1-31-B
  • HY-14427
    4E1RCat
    		Inhibitor 99.04%
    4E1RCat is an inhibitor of cap-dependent translation, and inhibits eIF4E:eIF4GI interaction, with an IC50 an of ～4 μM.
    4E1RCat
  • HY-149555
    DNL343
    		Activator 99.94%
    DNL343 is a potent, selective, orally active and brain-penetrant activator of eukaryotic initiation factor eIF2B. DNL343 inhibits the activity of the integrated stress response (ISR) in the central nervous system (CNS) and reverses neurodegeneration and neuroinflammation. DNL343 also prevents motor dysfunction and premature death in eIF2B loss-of-function (LOF) mutant mice. DNL343 can be used in the study of neurodegenerative diseases.
    DNL343
  • HY-160196
    HC-7366
    		Inhibitor 99.58%
    HC-7366 (GCN2 modulator-1) is an orally effective GCN2 activator. HC-7366 can effectively compete and occupy the ATP binding pocket of GCN2, with its IC50 being 72 nM. This binding triggers the conformational activation of GCN2, leading to the upregulation of downstream signals (such as ATF4, ASNS) in the integrated stress response (ISR) pathway, ultimately exerting anti-tumor effects. HC-7366 also has inhibitory activity against ZAK, with its IC50 being 47 nM. HC-7366 can be used for research on fibrosarcoma and acute myeloid leukemia.
    HC-7366
Cat. No. Product Name / Synonyms Application Reactivity